Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for Prevention of Cardiotoxicity in Breast Cancer
NCT06304857Phase 3Recruiting
- Sponsor
- 4th Military Clinical Hospital with Polyclinic
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dapagliflozin in Cardiotoxicity, sponsored by 4th Military Clinical Hospital with Polyclinic. Started Apr 2024; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT06304857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06304857.